The drug researcher and
Antibody specialist Morphosys comes with his
Application for approval of its agent tafasitamab for the treatment of a
certain form of lymphoma cancer in the United States. The
US FDA has accepted Morphosy’s application and
will tafasitamab in combination with the active ingredient lenalidomide
the MDax group announced on Monday in Planegg
Munich with. The FDA says it plans to ship by August 30
2020 on the approval of the antibody tafasitamab for the therapy of
therapy-resistant or recurring diffuse large
Decide B cell lymphoma (R / R DLBCL).
Tafasitamab is being developed with the partner Xencor. According to the
Xencor gets the terms of the cooperation and license agreement
now a milestone payment, Morphosys said. The height
was not named
ISIN DE0006632003
AXC0061 2020-03-02 / 07: 40
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.
– ,
